BIIB Stock Overview
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIIB from our risk checks.
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Biogen Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$160.85 |
52 Week High | US$268.30 |
52 Week Low | US$153.62 |
Beta | -0.081 |
11 Month Change | -7.45% |
3 Month Change | -21.52% |
1 Year Change | -29.93% |
33 Year Change | -29.09% |
5 Year Change | -45.88% |
Change since IPO | 5,116.76% |
Recent News & Updates
Recent updates
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Oct 31Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?
Oct 01What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E
Sep 04Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark
Aug 17Biogen Stock: Cheapish, But With Few Growth Prospects
Jul 11Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
May 23Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)
Apr 29Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Apr 28The Price Is Right For Biogen Inc. (NASDAQ:BIIB)
Apr 15We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings
Feb 21Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next
Feb 16Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)
Feb 14Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly
Jan 31Biotech And Pharma Diversification Pays Off
Jan 25Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult
Dec 26An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued
Oct 21Is Biogen (NASDAQ:BIIB) Using Too Much Debt?
Oct 03Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?
Jul 16Shareholder Returns
BIIB | US Biotechs | US Market | |
---|---|---|---|
7D | 2.0% | -0.8% | 0.4% |
1Y | -29.9% | 12.9% | 32.3% |
Return vs Industry: BIIB underperformed the US Biotechs industry which returned 12.9% over the past year.
Return vs Market: BIIB underperformed the US Market which returned 32.3% over the past year.
Price Volatility
BIIB volatility | |
---|---|
BIIB Average Weekly Movement | 3.1% |
Biotechs Industry Average Movement | 10.0% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIIB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BIIB's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1978 | 7,570 | Chris Viehbacher | www.biogen.com |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.
Biogen Inc. Fundamentals Summary
BIIB fundamental statistics | |
---|---|
Market cap | US$23.93b |
Earnings (TTM) | US$1.62b |
Revenue (TTM) | US$9.61b |
14.5x
P/E Ratio2.4x
P/S RatioIs BIIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIIB income statement (TTM) | |
---|---|
Revenue | US$9.61b |
Cost of Revenue | US$2.35b |
Gross Profit | US$7.26b |
Other Expenses | US$5.65b |
Earnings | US$1.62b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 11.08 |
Gross Margin | 75.59% |
Net Profit Margin | 16.81% |
Debt/Equity Ratio | 38.5% |
How did BIIB perform over the long term?
See historical performance and comparison